JP2005512998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005512998A5 JP2005512998A5 JP2003541837A JP2003541837A JP2005512998A5 JP 2005512998 A5 JP2005512998 A5 JP 2005512998A5 JP 2003541837 A JP2003541837 A JP 2003541837A JP 2003541837 A JP2003541837 A JP 2003541837A JP 2005512998 A5 JP2005512998 A5 JP 2005512998A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- lower alkyl
- substituted
- aminoquinoline
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 96
- 229910052739 hydrogen Inorganic materials 0.000 claims 50
- 239000001257 hydrogen Substances 0.000 claims 50
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 35
- 239000003430 antimalarial agent Substances 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 30
- 230000000078 anti-malarial effect Effects 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 241000124008 Mammalia Species 0.000 claims 21
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 21
- 150000005010 aminoquinolines Chemical class 0.000 claims 18
- 241000700605 Viruses Species 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 8
- 229960004171 hydroxychloroquine Drugs 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical class C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims 7
- 241000709661 Enterovirus Species 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 claims 5
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 5
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229960001441 aminoacridine Drugs 0.000 claims 5
- 229960003677 chloroquine Drugs 0.000 claims 5
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 229960001962 mefloquine Drugs 0.000 claims 5
- 229960000901 mepacrine Drugs 0.000 claims 5
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims 5
- 241000701161 unidentified adenovirus Species 0.000 claims 5
- 241000712461 unidentified influenza virus Species 0.000 claims 5
- 244000309467 Human Coronavirus Species 0.000 claims 4
- 229930013930 alkaloid Natural products 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 3
- 229940008126 aerosol Drugs 0.000 claims 3
- 239000006071 cream Substances 0.000 claims 3
- 239000003889 eye drop Substances 0.000 claims 3
- 229940012356 eye drops Drugs 0.000 claims 3
- 239000003885 eye ointment Substances 0.000 claims 3
- 239000006210 lotion Substances 0.000 claims 3
- 239000007922 nasal spray Substances 0.000 claims 3
- 229940097496 nasal spray Drugs 0.000 claims 3
- 201000009240 nasopharyngitis Diseases 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- RONWGALEIBILOG-VMJVVOMYSA-N quinine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 RONWGALEIBILOG-VMJVVOMYSA-N 0.000 claims 3
- HREHOXSRYOZKNT-UHFFFAOYSA-N quinolin-2-ylmethanol Chemical compound C1=CC=CC2=NC(CO)=CC=C21 HREHOXSRYOZKNT-UHFFFAOYSA-N 0.000 claims 3
- 210000001533 respiratory mucosa Anatomy 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 2
- FXVNYPZBTGPKQO-UHFFFAOYSA-N 4-n-(6-methoxyquinolin-8-yl)-1-n-propan-2-ylpentane-1,4-diamine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCNC(C)C)=C21 FXVNYPZBTGPKQO-UHFFFAOYSA-N 0.000 claims 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims 2
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 2
- 229960001444 amodiaquine Drugs 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- QTQWMSOQOSJFBV-UHFFFAOYSA-N pamaquine Chemical group C1=CN=C2C(NC(C)CCCN(CC)CC)=CC(OC)=CC2=C1 QTQWMSOQOSJFBV-UHFFFAOYSA-N 0.000 claims 2
- 229950000466 pamaquine Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229960005179 primaquine Drugs 0.000 claims 2
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- KXYNLLGPBDUAHW-UHFFFAOYSA-N quinolin-4-ylmethanol Chemical compound C1=CC=C2C(CO)=CC=NC2=C1 KXYNLLGPBDUAHW-UHFFFAOYSA-N 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- AFEAUYYSRPFHIA-UHFFFAOYSA-N 4-n-(7-chloro-3-methylquinolin-4-yl)-1-n,1-n-diethylpentane-1,4-diamine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=C(C)C=NC2=C1 AFEAUYYSRPFHIA-UHFFFAOYSA-N 0.000 claims 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010061494 Rhinovirus infection Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 *CCC1(*)CC(*)C2(C3=CCCCC3)NC(*)C(*)C(*)C2CC1 Chemical compound *CCC1(*)CC(*)C2(C3=CCCCC3)NC(*)C(*)C(*)C2CC1 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34587201P | 2001-11-09 | 2001-11-09 | |
| PCT/US2002/036309 WO2003039546A1 (en) | 2001-11-09 | 2002-11-12 | New uses for anti-malarial therapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512998A JP2005512998A (ja) | 2005-05-12 |
| JP2005512998A5 true JP2005512998A5 (enExample) | 2006-02-23 |
Family
ID=23356861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003541837A Pending JP2005512998A (ja) | 2001-11-09 | 2002-11-12 | 抗マラリア治療剤に対する新規の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040167162A1 (enExample) |
| EP (1) | EP1450803A4 (enExample) |
| JP (1) | JP2005512998A (enExample) |
| CN (1) | CN1289086C (enExample) |
| AU (1) | AU2002363443B2 (enExample) |
| CA (1) | CA2466338C (enExample) |
| IL (1) | IL161821A0 (enExample) |
| MX (1) | MXPA04004393A (enExample) |
| WO (1) | WO2003039546A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7084157B2 (en) * | 2002-05-17 | 2006-08-01 | Rajeev Raut | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| BR0318214A (pt) * | 2003-03-27 | 2006-03-21 | Council Scient Ind Res | análogos de 8-aminoquinolina substituìda no anel, composição anti-malárica, processo para a preparação de análogos de 8-aminoquinolina substituìda no anel, e, uso de análogos de 8-aminoquinolina substituìda no anel |
| US20070134596A1 (en) * | 2005-12-08 | 2007-06-14 | Adrian Lungu | Photosensitive printing element having nanoparticles and method for preparing the printing element |
| JP2009527478A (ja) * | 2006-02-16 | 2009-07-30 | ザ マクレーン ホスピタル コーポレーション | パーキンソン病の治療のための方法と組成物 |
| KR101067443B1 (ko) * | 2009-06-23 | 2011-09-27 | 여오영 | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 |
| CN103027915A (zh) * | 2011-09-29 | 2013-04-10 | 中国医学科学院基础医学研究所 | 氯喹治疗和氯丙嗪预防肺感染和损伤的用途 |
| CN103705516B (zh) * | 2013-12-11 | 2016-01-06 | 武汉威立得生物医药有限公司 | 氯喔星在制备治疗或预防流感病毒感染的药物中的应用 |
| KR101828553B1 (ko) * | 2016-04-15 | 2018-02-13 | 한국화학연구원 | 신규한 벤조싸이오펜 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물 |
| CA3029012C (en) * | 2016-06-28 | 2024-10-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Hycanthone derivatives and primaquine derivatives intended for use in preventing and/or treating conditions associated with Gammaherpesvirinae |
| CN111658648A (zh) * | 2020-02-03 | 2020-09-15 | 中国人民解放军军事科学院军事医学研究院 | 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用 |
| US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
| CN113046327B (zh) * | 2020-02-16 | 2022-05-10 | 北京化工大学 | 穿山甲冠状病毒xCoV及其应用和药物抗冠状病毒感染的应用 |
| US11638722B2 (en) | 2020-03-25 | 2023-05-02 | Therapeutica Borealis Oy C/O Avance Attorneys Ltd. | Medicine for Covid-19 and treatment |
| US11278602B2 (en) | 2020-03-25 | 2022-03-22 | Therapeutica Borealis Oy | Medicine for Covid-19 and treatment |
| WO2021191496A1 (en) * | 2020-03-25 | 2021-09-30 | Therapeutica Borealis Oy | Medicine for covid-19 and treatment |
| US11007187B1 (en) * | 2020-03-25 | 2021-05-18 | Therapeutica Borealis Oy | Medicine for Covid-19 and treatment |
| WO2021204717A1 (en) * | 2020-04-06 | 2021-10-14 | Oxandia Ltd | Aminoquinolines for treating coronavirus infections |
| EP3892275A1 (en) * | 2020-04-08 | 2021-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosolization of hcq or its metabolites for the treatment of lung infections |
| EP4135673A4 (en) * | 2020-04-14 | 2024-05-08 | Glanis Pharmaceuticals, Inc. | TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE |
| JP2023523035A (ja) * | 2020-04-21 | 2023-06-01 | コーエン ノーム | キニーネ及び先天性免疫応答を生じさせるためのその使用 |
| AU2021261049A1 (en) * | 2020-04-24 | 2022-11-10 | Topelia Aust Limited | Products of manufacture and methods for treating, ameliorating or preventing microbial infections |
| US20230165851A1 (en) * | 2020-04-27 | 2023-06-01 | Immunologik Gmbh | 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections |
| CN115515935B (zh) * | 2020-04-30 | 2025-01-07 | 中美华世通生物医药科技(武汉)股份有限公司 | 冠状病毒感染的治疗或预防 |
| JP2023541241A (ja) * | 2020-09-14 | 2023-09-29 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | ヒドロキシクロロキンを含む医薬組成物およびその使用 |
| DE102021000717A1 (de) * | 2021-02-12 | 2022-08-18 | Forschungszentrum Jülich GmbH | Quinacrin als lnhibitor viraler Cysteinproteasen und/oder Serinproteasen |
| US20240391876A1 (en) * | 2021-08-19 | 2024-11-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Quinacrine and derivatives thereof for treatment of viral infections |
| CN115869311A (zh) * | 2022-12-30 | 2023-03-31 | 湖北工业大学 | MefloquineHydrochloride在制备抗腺病毒ADV7药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4181725A (en) * | 1977-05-02 | 1980-01-01 | The Regents Of The University Of Michigan | Method for alleviating psoriasis |
| US4496549A (en) * | 1983-01-17 | 1985-01-29 | American Cyanamid Company | Treatment of malaria with antibiotics |
| US5153202A (en) * | 1988-06-30 | 1992-10-06 | Davis Michael H | Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo |
| US5376359A (en) * | 1992-07-07 | 1994-12-27 | Glaxo, Inc. | Method of stabilizing aerosol formulations |
| US5827681A (en) * | 1996-12-20 | 1998-10-27 | University Technology Corporation | Rapid detection and drug sensitivity of malaria |
| EP1175216A2 (en) * | 1999-04-30 | 2002-01-30 | APT Pharmaceutical, L.L.C. | Antimalarian agents for the treatment of asthma |
-
2002
- 2002-11-12 WO PCT/US2002/036309 patent/WO2003039546A1/en not_active Ceased
- 2002-11-12 CA CA002466338A patent/CA2466338C/en not_active Expired - Fee Related
- 2002-11-12 US US10/293,770 patent/US20040167162A1/en not_active Abandoned
- 2002-11-12 CN CNB028267923A patent/CN1289086C/zh not_active Expired - Fee Related
- 2002-11-12 MX MXPA04004393A patent/MXPA04004393A/es not_active Application Discontinuation
- 2002-11-12 JP JP2003541837A patent/JP2005512998A/ja active Pending
- 2002-11-12 AU AU2002363443A patent/AU2002363443B2/en not_active Ceased
- 2002-11-12 IL IL16182102A patent/IL161821A0/xx unknown
- 2002-11-12 EP EP02802902A patent/EP1450803A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512998A5 (enExample) | ||
| CA2466338A1 (en) | New uses for anti-malarial therapeutic agents | |
| US20250361211A1 (en) | Deuterated cftr potentiators | |
| AU2021200970B2 (en) | Deuterated derivatives of ivacaftor | |
| US10047053B2 (en) | Deuterated CFTR potentiators | |
| US10759721B2 (en) | Deuterated CFTR potentiators | |
| JP6146990B2 (ja) | 重水素化されたｃｆｔｒ増強物質 | |
| CA2372443A1 (en) | Local administration of anti-malarial agents for the treatment of inflammatory diseases | |
| JP2007008816A (ja) | 新規イソキノリン誘導体 | |
| US20070155788A1 (en) | Quinoline Inhibitors of cGMP Phosphodiesterase | |
| SG186821A1 (en) | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds | |
| EP1548008A1 (en) | Compound having tgf-beta inhibitory activity and medicinal composition containing the same | |
| JP2019521092A (ja) | ヒストン脱アセチル化酵素６阻害剤およびその使用 | |
| Horta et al. | Quinolones for Applications in Medicinal Chemistry: Synthesis and Structure | |
| US20210130349A1 (en) | Novel phosphodiesterase inhibitors and uses thereof | |
| CN109364075B (zh) | 氘化cftr增效剂 | |
| JP2007511570A5 (enExample) | ||
| WO2011091035A1 (en) | Aminoquinoline derivatives | |
| JP2900130B2 (ja) | カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤 | |
| KR102070361B1 (ko) | 중수소화 ｃｆｔｒ 강화제 | |
| HK40004908A (en) | Deuterated cftr potentiators | |
| WO2024073624A2 (en) | Antiproliferative betti bases and prodrugs thereof | |
| HK40004908B (zh) | 氘化 cftr 增效剂 | |
| HK1244183B (en) | Deuterated derivatives of ivacaftor | |
| JP2017105824A (ja) | 重水素化されたｃｆｔｒ増強物質 |